IASLC WCLC 2020: Addition of sintilimab to pemetrexed and platinum improved progression-free survival in NSCLC

Pinterest LinkedIn Tumblr +

The interim analysis of ORIENT-11, a phase III double-blind randomised trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.

The research findings are also published simultaneously in the Journal of Thoracic Oncology, the journal of the International Association for the Study of Lung Cancer.

Previously, sintilimab in combination with pemetrexed and a platinum-based chemotherapy had shown promising activity for nonsquamous non small cell lung cancer in a phase 1b study, according to Li Zhang, M.D., of Sun Yat-sen University Cancer Center, Guangzhou, China.

Dr. Zhang and investigators from centres in China enrolled 397 patients in the study.

Of these, 266 and 131 patients were randomly assigned to the sintilimab combination and to placebo combination, respectively.

Patients with all ranges of PD-L1 expression (by tumour proportion score, TPS) were included.

The median progression free survival per was significantly improved in sintilimab-combination group compared to placebo combination group (8.9 vs. 5.0 months).

Dr. Zhang reported that sintilimab-combination group showed a nominally significant improvement of overall survival.

The overall response rate also was improved for the sintilimab-combination group (51.9% versus 29%).

The safety signal for the sintilimab combination was similar to that found in other studies, but rates of occurrence of grade > 3 adverse events were slightly higher in the sintilimab-combination group (61.7% versus 58.8%).

“This study demonstrated that the addition of sintilimab to chemotherapy significantly improved progression-free survival and a nominally improved overall survival, with an acceptable safety profile in [patients with]first-line non-squamous non small cell lung cancer,” said Dr. Zhang. “In this study, we collected tumour samples at baseline of treatment. So, our next work will focus on biomarker exploration. By RNA sequencing of tumour samples, we look forward to searching a potential biomarker which can predict the survival benefit from PD-1 combination with chemotherapy.”

Source:The International Association for the Study of Lung Cancer (IASLC)


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.